Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OxyMAX: MDMA in Central Diabetes Insipidus
NCT06789705Recruiting
- Sponsor
- University Hospital Basel
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of midomafetamine in central diabetes insipidus (CDI) (2 arms), sponsored by University Hospital Basel. Primary endpoint: Area under the concentration-time curve in plasma oxytocin level up to 6 weeks. Started Jan 2025; status: recruiting.
02
Drugs
midomafetamine
03
Conditions
central diabetes insipidus (CDI)
Beyond the preview
Go deeper on NCT06789705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06789705.